SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 07 2021
Historique:
received: 03 03 2021
accepted: 21 06 2021
entrez: 20 7 2021
pubmed: 21 7 2021
medline: 28 7 2021
Statut: epublish

Résumé

In February and March 2020, two mass swab testing campaigns were conducted in Vo', Italy. In May 2020, we tested 86% of the Vo' population with three immuno-assays detecting antibodies against the spike and nucleocapsid antigens, a neutralisation assay and Polymerase Chain Reaction (PCR). Subjects testing positive to PCR in February/March or a serological assay in May were tested again in November. Here we report on the results of the analysis of the May and November surveys. We estimate a seroprevalence of 3.5% (95% Credible Interval (CrI): 2.8-4.3%) in May. In November, 98.8% (95% Confidence Interval (CI): 93.7-100.0%) of sera which tested positive in May still reacted against at least one antigen; 18.6% (95% CI: 11.0-28.5%) showed an increase of antibody or neutralisation reactivity from May. Analysis of the serostatus of the members of 1,118 households indicates a 26.0% (95% CrI: 17.2-36.9%) Susceptible-Infectious Transmission Probability. Contact tracing had limited impact on epidemic suppression.

Identifiants

pubmed: 34282139
doi: 10.1038/s41467-021-24622-7
pii: 10.1038/s41467-021-24622-7
pmc: PMC8289856
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0
Spike Glycoprotein, Coronavirus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4383

Subventions

Organisme : Wellcome Trust
ID : 203851/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 213494/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s).

Références

Science. 2021 Feb 19;371(6531):
pubmed: 33323424
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Reprod Biomed Online. 2020 Sep;41(3):483-499
pubmed: 32651106
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
Wellcome Open Res. 2020 Oct 13;5:239
pubmed: 33154980
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22430-22435
pubmed: 32820074
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Postgrad Med J. 2021 Mar;97(1145):143-149
pubmed: 33115909
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Epidemics. 2021 Sep;36:100477
pubmed: 34171509
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Infect Dis. 2021 Aug 2;73(3):e754-e764
pubmed: 33560412
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Science. 2020 May 8;368(6491):
pubmed: 32234805
Science. 2021 Jan 15;371(6526):
pubmed: 33234698
Am J Epidemiol. 2011 Sep 1;174(5):505-14
pubmed: 21749971
Clin Transl Immunology. 2020 Sep 26;9(9):e1182
pubmed: 33005417
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Ilaria Dorigatti (I)

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK. i.dorigatti@imperial.ac.uk.

Enrico Lavezzo (E)

Department of Molecular Medicine, University of Padova, Padova, Italy. enrico.lavezzo@unipd.it.

Laura Manuto (L)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Constanze Ciavarella (C)

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.

Monia Pacenti (M)

Azienda Ospedale Padova, Padova, Italy.

Caterina Boldrin (C)

Azienda Ospedale Padova, Padova, Italy.

Margherita Cattai (M)

Azienda Ospedale Padova, Padova, Italy.

Francesca Saluzzo (F)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Elisa Franchin (E)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Claudia Del Vecchio (C)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Federico Caldart (F)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Gioele Castelli (G)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Michele Nicoletti (M)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Eleonora Nieddu (E)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Elisa Salvadoretti (E)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Beatrice Labella (B)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Ludovico Fava (L)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Simone Guglielmo (S)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Mariateresa Fascina (M)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Marco Grazioli (M)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Gualtiero Alvisi (G)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Maria Cristina Vanuzzo (MC)

Azienda Ospedale Padova, Padova, Italy.

Tiziano Zupo (T)

Azienda Ospedale Padova, Padova, Italy.

Reginetta Calandrin (R)

Azienda Ospedale Padova, Padova, Italy.

Vittoria Lisi (V)

Azienda Ospedale Padova, Padova, Italy.

Lucia Rossi (L)

Azienda Ospedale Padova, Padova, Italy.

Ignazio Castagliuolo (I)

Department of Molecular Medicine, University of Padova, Padova, Italy.

Stefano Merigliano (S)

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

H Juliette T Unwin (HJT)

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.

Mario Plebani (M)

Department of Medicine, University of Padova, Padova, Italy.

Andrea Padoan (A)

Department of Medicine, University of Padova, Padova, Italy.

Alessandra R Brazzale (AR)

Department of Statistical Sciences, University of Padova, Padova, Italy.

Stefano Toppo (S)

Department of Molecular Medicine, University of Padova, Padova, Italy.
CRIBI Biotech Centre, University of Padova, Padova, Italy.

Neil M Ferguson (NM)

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.

Christl A Donnelly (CA)

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK.
Department of Statistics, University of Oxford, Oxford, UK.

Andrea Crisanti (A)

Department of Molecular Medicine, University of Padova, Padova, Italy. a.drcrisanti@imperial.ac.uk.
Azienda Ospedale Padova, Padova, Italy. a.drcrisanti@imperial.ac.uk.
Department of Life Science Imperial College London, Exhibition Road, London, UK. a.drcrisanti@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH